Amylin, Amazon, and the Cloud



By Kevin Davies

November 30, 2009
| It was last year when Amylin CIO Steve Phillpott knew he had a space problem. With his two San Diego datacenters perilously close to capacity, housing close to 700 servers and about 200 Terabytes of data, he was contemplating building a third data center in Las Vegas or Phoenix. But the notion of enabling a virtual organization appealed to the IT industry veteran, hence he chose to leverage the cloud.

Unlike most other big pharma companies, which might have one specific application in the cloud, Phillpott and colleagues took a broader view. “We wanted to build capabilities in several different areas,” says Phillpott. As the biotech’s business needs evolve, Phillpott’s staff can decide on the best tool for the particular business need.

Over the past year, Phillpott has built up Virtual Data Center capabilities in four major areas using Amazon EC2 and other providers. First is a pure infrastructure for quick provisioning (adding and subtracting) servers. “We actually have connectivity to Amazon,” says Phillpott. “Amazon is just an extension of my data center here. I can add applications up there.” Phillpott currently has four business apps running on EC2. “The beauty of it is I have secure connectivity so it looks like my data center.”

Second is software development tools, or what Phillpott calls “the Lego building blocks of building an application.” Often he doesn’t want to build an application from scratch, but rather pick apps off the shelf, such as Google Apps and Salesforce.com platform (Force.com).
The third area is support for disaster recovery—building capabilities to maintain images of Amylin’s servers and data using a cloud storage company called Nirvanix. “Now I’ve got a snapshot of every server in the organization stored within Nirvanix’ datacenter, such that if something was to happen to one of those servers, I could quickly rebuild it someplace else, like Amazon!” (Nirvanix competes with Amazon’s S3.)

The fourth area is the actual application of software-as-a-service (SaaS). Phillpott considers what applications are sitting on Amylin’s systems where he doesn’t want to support the hardware and software going forward. “All I want to do is rent to be a more variable model. If I add 100 people, I add 100 people times X dollars a month.” For example, Phillpott is migrating Amylin’s email solution, and considering some other large applications so that they’d be provided by SaaS.

Secure Environment
A lot of companies have shied away from the cloud citing security concerns. Phillpott took the opposite tack: “The cloud’s here, it’s going to be here to stay, and I’m looking for applications that make sense out there.” Not every application fits the cloud, he says, but he’s already proven that a lot of apps do fit. “We’re starting to build maturity, capability, and a knowledge base, knowing that as we build that out, the industry matures and I can then keep moving more and more.”

The first Amylin apps running on EC2 are internal personal apps outside the R&D space. “We wanted to build a very solid security model before we tackled some of the R&D use cases,” says Phillpott. Those early examples include commercial sales (territory management), human resources (performance management), and some security apps. The savings are typically about 50% he says. Speed and performance considerations will inevitably become more important as Amylin runs more R&D apps.

Phillpott provisioned the first server at Amazon personally. It took him all of 15 minutes. “Now I haven’t provisioned a server in 10 years—that’s how easy it is!” he says. He showed his results to Amylin’s director of applications, and from that point on, his team was determined to outperform the CIO.

Lately, for some of the more complex scheduling, Phillpott has been working with Cycle Computing (see p. 28) in the research and genomics space. Another partner is a San Diego firm called Cirrhus 9, which has been helping Amylin on a couple of other cloud aspects.

Asked to comment on EC2’s performance, Phillpott says simply, “we’re very pleased. It’s taken us a long time to get to this place, because we wanted a solid security model.”  Indeed, Phillpott says the EC2 security is greater than in most corporate environments he’s seen, although it is still improving.

However, Amazon is not the only game in town. “There are lots of companies coming into this space right now, but I don’t think all of them will be around in three years,” says Phillpott. “We want to ensure that, as we’re in the learning stage, we’re learning with someone who we’re confident will be around.” In a few years, once he has more expertise and the market matures, then “you bet,” he’ll entertain other options. 

Reframing the IT Mindset
Aside from the obvious security questions, Phillpott says another key issue surrounds the mindset of the IT group, which worried that the cloud would limit or reduce career opportunities. “People at first thought, if we move everything out to the cloud, how will that affect me?” Phillpott recalls. “Over the last year, we’ve really educated them that, ‘No, it changes your skill set, it doesn’t do away with your job. I still need you to do things, it’s just that I need you to do higher-value tasks, focused on innovation and core business competencies, rather than commodity, keeping-the-lights-on activities.’”

Phillpott cites the example of applications being built up on Force.com. “The developers initially thought Force.com would replace the need for internal development. Once they tried building their first Force.com application, they said, ‘Oh, this just makes us more productive.’” Reframing is a real issue, like recoding a workflow application, he says.

Another issue is performance and latency. “For the most part, we’ve been setting up good solid connectivity with Amazon. I haven’t had to send massive datasets, but I’m identifying a couple of other applications that require sending large amounts of data in a couple of months. That will really test the connectivity.”

Like many others, Phillpott is also looking at internal virtualization and private clouds using VMware. This would be a complement to EC2, he says. “My goal is to have capabilities in these different areas, so when the business comes, I can decide: What is the best tool for that particular job? I don’t want to be forced into having a hammer and everything’s a nail—I have EC2 so everything has to fit there. I think we’re in a nice position where we have half-a-dozen different tools, and I can do the best selection based on cost, control, performance and security, as to which is the best fit.” 


This article also appeared in the November-December 2009 issue of Bio-IT World Magazine.
Subscriptions are free for qualifying individuals. Apply today.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .